Safety study of ABF-101 in healthy people and AMD patients
Part of Eyes & vision clinical trials.
This trial tests the safety of a new drug called ABF-101 in two groups: healthy volunteers (Part A and B) and people with age-related macular degeneration (AMD, Part C). If you join, you will help researchers understand how the drug affects the body and if it's safe enough to study further.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be a healthy adult aged 18 to 50 for Parts A and B.
- For Part C, you must be at least 50 years old and have a confirmed diagnosis of AMD.
- You must be a nonsmoker and willing to avoid caffeine, alcohol, and strenuous activity during the study.
- You must not take any medications except for acetaminophen (Tylenol) or birth control.
- You cannot have any heart, lung, stomach, liver, kidney, blood, nerve, or mental health conditions.
- You must agree to use effective birth control if you or your partner could become pregnant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medicine called AB102 in healthy people to see if it is safe and how the body processes it. It may help researchers understand the right dose for future studies.
This trial tests an investigational drug called EG-301 for people with dry age-related macular degeneration (AMD) that causes geographic atrophy, a type of vision loss. The study aims to see if the drug can slow or stop the progression of the disease.
This study tests a new medicine called IBI302 for wet age-related macular degeneration (AMD). It aims to slow vision loss by targeting both blood vessel growth and inflammation. You might qualify if you have active wet AMD and have not had certain injections recently.
This study tests a new medicine called ARO-033 for people with age-related macular degeneration (AMD), a common eye condition that can cause vision loss. The trial will see if the medicine is safe and how it affects the body.
This trial tests an investigational drug called AMDX-2011P for people with Alzheimer's disease. It looks at whether the drug affects the retina, which may be linked to brain changes in Alzheimer's.
This study is creating a library of eye images to help doctors better diagnose age-related macular degeneration (AMD). You can join if you have healthy eyes or any stage of AMD that has never been treated.
Hear when a new Age-related Macular Degeneration (ARMD) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.